About i2C Pharma
i2C Pharmaceutical Services is a leading independent service provider to the global pharma, medical technology companies and emerging clients for the development of pharmaceutical formulations and inhaler devices from its facilities in Cardiff, Wales. Established over30 years ago i2C have built a wealth of experience and knowledge in respiratory pharmaceutical formulation, device development and research. i2C have provided support for more than 50 different pharma companies.
Board Of Directors
Andrew Brown, PhD
CEO
30 years experience in Product Development, and Device Development at GSK, Oriel and OBG
John Pritchard PhD
Chairman
30 years experience in Product Development, and Device Development at GSK, Oriel and OBG
Professor Glyn Taylor, PhD
CSO, (Founding Director)
30 years experience in Product Development, and Device Development at GSK, Oriel and OBG
Simon Warren, PhD
Research Director
30 years experience in Product Development, and Device Development at GSK, Oriel and OBG
Rhodri Turner, PhD
Non-Executive Director
30 years experience in Product Development, and Device Development at GSK, Oriel and OBG
What We Offer
i2C Pharma Services provides independent R&D of inhaler formulations and devices for global pharma, medtech and emerging clients.
Well-Established
We have been working in inhalation and Medical Devices for more than 30 years.
Innovation
Experts at providing innovative solutions to customer technical challenges. Have developed IP in the MDI field.
Unique Offering
Have a facility fully integrated within a 48-bed bed CRO.
Technical Expertise
Experts in Gamma Scintigraphy and MDI development with over 30 publications.
Customer Focused
Provide responsive and flexible project management to support customers to achieve challenging timelines.
Mission Statement
To deliver high-quality, independent research and development services for inhaler formulations and devices, supporting global pharmaceutical and medtech clients from concept to clinic with expertise, integrity, and efficiency
Vision Statement
To be the trusted partner of choice for innovative inhalation drug development, advancing respiratory health through scientific excellence and client-focused solutions